清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial

医学 内科学 西妥昔单抗 临床终点 不利影响 耐火材料(行星科学) 临床研究阶段 置信区间 生活质量(医疗保健) 临床试验 肿瘤科 胃肠病学 外科 癌症 结直肠癌 物理 护理部 天体生物学
作者
Jürgen C. Becker,Anja Gesierich,Ulrike Leiter,Lisa Zimmer,Jessica C. Hassel,Imke von Wasielewski,Mirjana Ziemer,Michael Fluck,Friedegund Meier,Alexandra N Spillner,Bastian Schilling,Thomas Eigentler,Elisabeth Livingstone,Selma Ugurel,Yenny Angela,Christine Windemuth-Kieselbach,Ralf Gutzmer
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:193 (5): 865-875 被引量:3
标识
DOI:10.1093/bjd/ljaf303
摘要

BACKGROUND: In cutaneous squamous cell carcinoma (cSCC), programmed cell death protein 1 (PD-1) and epidermal growth factor receptor (EGFR) inhibitors are effective in a considerable proportion of patients. However, there is an unmet medical need for patients with perianogenital cSCC or cSCC refractory to PD-1 therapy. OBJECTIVES: To evaluate the combination avelumab (programmed death ligand 1 inhibitor) and cetuximab (EGFR inhibitor) in people with advanced cSCC treated for up to 1 year. METHODS: This multicentre phase II trial enrolled patients with advanced cSCC (prior systemic therapy allowed) to receive avelumab (10 mg kg-1 Q2W) plus cetuximab (500 mg m-2 Q2W) for up to 1 year. The primary endpoint was objective response. Predefined subgroups were line of therapy and localization of the primary tumour (perianogenital/other locations). RESULTS: Of 52 enrolled patients, 49 received at least 1 treatment dose. Of these patients, 20 achieved an objective response [41%, 95% confidence interval (CI) 27-56; 9 partial responses/11 complete responses (CRs)]. While treatment-naïve patients (n = 35) achieved a higher objective response rate (46%, 95% CI 29-63) than those who were pretreated (29%, 95% CI 8-58), 4 of 14 pretreated patients experienced an objective response, 2 with prior PD-1 inhibition. Five of 14 patients with perianogenital cSCC achieved an objective response (36%, 95% CI 13-65), including 4 CRs. At a median follow-up of 35 months, median progression-free and overall survival were 8.4 and 23.1 months, respectively. Grade 1 and 2 treatment-related adverse events (TRAEs) were common, while grade ≥ 3 events occurred in only 10 patients (20%) and 7 experienced serious TRAEs (14%); 2 discontinued treatment due to drug-related toxicity. Notably, quality of life improved, especially in patients with perianogenital primaries. CONCLUSIONS: Avelumab in combination with cetuximab demonstrates encouraging clinical activity in advanced cSCC, including patients with challenging subgroups such as perianogenital primaries or those with disease that has progressed on anti-PD-1 monotherapy. This is especially true when patients are carefully selected for their ability to undergo treatment for at least 12 weeks.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
优秀函完成签到,获得积分10
2秒前
3秒前
MchemG举报JiaYouguo的求助涉嫌违规
10秒前
11秒前
NN的应助被萧雨墨采纳,获得10
18秒前
18秒前
Aaron发布了新的文献求助10
24秒前
搞怪的方盒完成签到,获得积分10
29秒前
CipherSage的应助被whc采纳,获得10
36秒前
科研通AI65的应助被amiee采纳,获得10
41秒前
50秒前
52秒前
lyn123发布了新的文献求助10
58秒前
所所的应助被葛力采纳,获得10
59秒前
1分钟前
1分钟前
小马甲的应助被lyn123采纳,获得10
1分钟前
Wang完成签到 ,获得积分20
1分钟前
直率的大门完成签到,获得积分10
1分钟前
陆上飞完成签到,获得积分10
1分钟前
lyn123完成签到,获得积分10
1分钟前
JUN完成签到,获得积分10
1分钟前
1分钟前
zy997987876完成签到,获得积分10
1分钟前
Owen的应助被NavidWarren139采纳,获得40
2分钟前
MchemG举报大点的求助涉嫌违规
2分钟前
2分钟前
大医仁心完成签到 ,获得积分0
2分钟前
潇洒小海豚完成签到,获得积分10
2分钟前
2分钟前
3分钟前
3分钟前
淡定的夜云完成签到 ,获得积分10
3分钟前
3分钟前
3分钟前
圈圈圆了发布了新的文献求助100
3分钟前
3分钟前
3分钟前
顺心的一德完成签到,获得积分10
3分钟前
圈圈圆了完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190159
求助须知:如何正确求助?哪些是违规求助? 9577264
关于积分的说明 21852314
捐赠科研通 7788621
什么是DOI,文献DOI怎么找? 3436279
关于科研通互助平台的介绍 2560058
邀请新用户注册赠送积分活动 2482880